FibriCheck is aware of the Log4j zero-day vulnerability in the Java logging framework. This vulnerability is being tracked as CVE-2021-442281/2 and currently has the highest severity score [10/10]. Therefore our technical team immediately started an internal investigation, on Saturday, December…
Atrial fibrillation (AF) is the most common heart rhythm disorder. People as young as 40 have a 1 in 4 chance of developing AF in their lifetime, making them 5 times more likely to suffer a stroke. In an effort…
On the occasion of Heart Rhythm Week, the Belgian Heart Rhythm Association (BeHRA) in association with FibriCheck is organising a nationwide campaign to raise awareness of remote heart rhythm monitoring for 10,000 people who are at risk.
FibriCheck, the app capable of detecting heart rhythm disorders like atrial fibrillation, is now available in Australia for use with compatible smartphones (both iPhone and Android) as well as selected smartwatches. This means that the more than 500.000 Australians at…
Atrial Fibrillation (AF) is one of the leading causes of stroke and often goes undiagnosed due to lack of symptoms.1 It is estimated that 300,000 people are living with undiagnosed AF and that over 2,000 lives could be saved every…
Hasselt, February 3, 2021 - Qompium, the pioneering Belgian digital health company, has received an additional 9 million euros in funding after a new capital round. With its business units FibriCheck (medical app which detects heart rhythm disorders) and Extra Horizon (secure,…
As TeleCheck AF continues to gain traction across the continent, notable strides are being made in the UK, where recently published guidelines cite FibriCheck’s remote heart rhythm monitoring as an example of clinical best practice in the delivery of care for cardiovascular disease…
It’s been an exciting year for FibriCheck! And looking back at everything we achieved together with our partners in 2020, it’s remarkable how many milestones we have reached and surpassed. Read on for a brief overview of the year that…
People suffering from potential heart rhythm disorders will soon be able to sleep a little easier. Because FibriCheck’s (semi-)continuous heart rhythm monitoring technology was recently granted CE approval by the European authorities. This is a major leap forward towards a future where users…
FibriCheck enables large scale teleconsultations at Maastricht University Medical Centre+